Raymond James initiated coverage of Avidity Biosciences (RNA) with a Strong Buy rating and $65 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS – probability of success – lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the company, the firm cites its high conviction in del-zota becoming the first approved drug from Avidity’s antibody oligonucleotide conjugate – AOC – platform, Raymond James added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences Holds 2025 Annual Stockholder Meeting
- Avidity Biosciences: Promising Developments and FDA Endorsement Position for Potential Regulatory Approvals by 2027
- Avidity Biosciences price target raised to $75 from $70 at Citi
- Avidity Biosciences price target raised to $59 from $57 at Barclays
- Avidity data strengthens accelerated approval case, says H.C. Wainwright